Lee’s Pharmaceutical Holdings Limited ((HK:0950)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Lee’s Pharmaceutical Holdings Limited is conducting a Phase III clinical trial to evaluate the efficacy of 5-aminolevulinic acid hydrochloride (5-ALA HCl) in fluorescence-guided microsurgery compared to conventional white light microsurgery for patients with malignant gliomas (WHO Grade 3/4). The study aims to improve the precision of tumor resections, potentially enhancing patient outcomes.
The intervention being tested is 5-aminolevulinic acid, an oral solution used to guide fluorescence-based tumor resection. This approach is designed to increase the accuracy of tumor removal during surgery.
The study is a randomized, open-label, parallel-group, multicenter trial with a diagnostic primary purpose. It involves no masking, allowing for direct comparison between the experimental and control groups.
The study began on November 27, 2023, with an estimated primary completion date in 2025. The latest update was submitted on May 9, 2025, indicating ongoing progress.
This clinical trial update could positively influence Lee’s Pharmaceutical’s stock performance by showcasing innovation in surgical techniques. It may also affect investor sentiment, particularly if the results demonstrate significant improvements over conventional methods. Competitors in the oncology field may need to consider similar innovations to remain competitive.
The study is currently recruiting, with further details available on the ClinicalTrials portal.